Creative Proteomics Launches Oncology Multi-omics Platform to Promote Basic Oncology Research
Using its mature multi-omics technology platform, Creative Proteomics has been devoted to providing high-quality, personalized oncology multi-omics services and reliable data support to worldwide clients for years.
With the continuous aging of human society, the improvement of industrialization, and the deterioration of the quality of living environment, the incidence of cancer is getting higher and higher. Elucidating the mechanisms of tumorigenesis is utterly dire and a crucial research topic. The use of proteomics can comprehensively, dynamically and quantitatively analyze the changes of protein types and quantities in normal and cancerous specimens, which not only can help to elucidate the pathogenesis of tumors but can also screen and identify tumor-specific markers and specific antigens. It can then be further applied to the early diagnosis and treatment of tumors, and in addition, guide the development of new cancer treatment.
Proteomics is increasingly used in oncology research, and more specifically, mass spectrometry-based proteomics is mainly applied in the following three research directions:
1. Comparing the differential changes in the expression of a large number of proteins in different normal and tumor samples or samples under different treatment conditions.
2. Large-scale analysis of post-translational modification sites in proteins and the changes in protein modification levels under different conditions.
3. Resolving protein complex composition or protein interaction relationships and networks.
Currently, there are two main ideas and modes of mass spectrometry-based proteomics research: differential comparative proteomics and identification proteomics.
CES University Graduate School in Medellin, Colombia conducted a study of human and bacterial proteomic profiles in bile exposed to tumor and non-tumor microenvironments in order to better understand the mechanisms of pancreatic cancer development and the role of bacterial carcinogenesis and to determine the difference between these conditions. Creative Proteomics conducted the proteomic analysis for the research group. A total of 20 bile samples from the gallbladder, 7 from GS patients and 13 from PDAC patients, were analyzed for this project. The bile clinical samples were first pre-treated to precipitate total protein and remove impurities. The proteins were then enriched and purified by nano liquid chromatography, followed by mass spectrometry and data analysis to qualitatively and quantitatively analyze the protein profile in the microenvironment. In the total proteome, three biological pathways related to bacterial infection were found. The results showed that bacteria may be a key factor in the occurrence of biliary tract cancer.
If you are interested and want to learn more, please visit https://tumomics.creative-proteomics.com/ for more information.
About Creative Proteomics
Creative Proteomics is a professional multi-omics provider serving researchers in the pharmaceutical, biotechnology, agricultural and nutrition industries, as well as academia and government agencies. With a continued focus on quality, Creative Proteomics is proud to meet our worldwide clients’ needs.
Address: Shirley, NY 11967, USA